Noven Expects Second Quarter Earnings To Exceed Prior Public Guidance

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that, based on a preliminary review of its financial results for the June 30 quarter, it expects to exceed its prior public earnings guidance for the second quarter of $0.14 to $0.17 per share.

"We had forecast a strong second quarter, and we now expect that earnings will be even better than our most recent guidance," said Robert C. Strauss, Noven's President, CEO & Chairman. "We plan to announce second quarter financial results on or about August 1, and expect to update our full-year guidance at that time."

This release contains forward-looking statements related to the business of Noven that can be identified by the use of forward-looking terminology such as "expects" and "plans" and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven's most recent filings with the Securities and Exchange Commission and in this press release, including the risk that actual second quarter results may not exceed Noven's most recent public guidance because of issues identified in Noven's and its independent accountant's review of the second quarter financial results, including potential GAAP adjustments that may negatively impact earnings.

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a highly profitable women's health products company called Novogyne Pharmaceuticals. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot®, licensed to Novogyne, and Estradot®, licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch®, licensed to Novogyne, and Estalis®, licensed to Novartis Pharma AG). With a range of additional products in development, including MethyPatch®, Noven is committed to becoming the world's premier developer, manufacturer and marketer of transdermal drug delivery systems. For additional information, visit Noven's website at www.noven.com.

This release contains forward-looking statements related to the business of Noven that can be identified by the use of forward-looking terminology such as "hopeful", "will" and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven's most recent filings with the Securities and Exchange Commission and in this press release, including the risk that physicians and patients will extrapolate the study results to transdermal HRT products and that prescription growth of Noven's products, as well as Noven's financial results, will be adversely affected.

Contact:
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916